ArticleRisk management and healthcare policy2026
Migraine Prevalence and QALY Loss in Serbia: A Population-Level Stratified Modeling Study.
Article in Risk management and healthcare policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To estimate age- and sex-specific migraine prevalence in Serbia and annual quality-adjusted life-year (QALY) loss among adults with definite or probable migraine using a population-level stratified model. Methods: Global Burden of Disease (GBD) 2023 prevalence estimates for definite migraine, probable migraine, and total medication-overuse headache (MOH) in Serbia were applied to final 2022 Serbian Census counts by single year of age and sex; 73.2% of total MOH was attributed to migraine. Epidemiological estimates included residents aged 5 years or older, whereas the primary one-year QALY analysis included adults aged 18 years or older with definite or probable migraine. Annual QALY loss equaled modeled case counts multiplied by the GBD 2023 proportion of time symptomatic and the paired EQ-5D-5L migraine-day utility decrement of 0.364. A 100,000-iteration probabilistic sensitivity analysis sampled 12 symptom-time parameters and one shared utility-decrement parameter from normal distributions truncated to [0,1], with prevalence fixed. No episodic/chronic split or attack-frequency assumptions were imposed. Results: The model estimated 952,369 residents aged 5 years or older with migraine (crude modeled prevalence, 15.0%). Among adults, 794,380 with definite or probable migraine were included in the primary QALY analysis, whereas 85,364 with MOH attributable to migraine were reported epidemiologically only. Deterministic annual QALY loss was 21,951, or 0.0276 QALY (10.1 full-health-equivalent days) per included adult. Across 100,000 probabilistic iterations, mean annual loss was 21,949 QALYs (95% uncertainty interval, 20,203-23,736). Conclusion: Migraine represents a substantial modeled population-health burden in Serbia. The primary estimate excluded pediatric, MOH-related, and additional interictal QALY loss. It provides a transparent national benchmark for migraine recognition, referral, health-related quality-of-life measurement, and evaluation of preventive-care access, but does not establish intervention effectiveness or cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.